Fumitaka Suto

8PUBLICATIONS
88CO-AUTHORS
Molecular targetsCancer therapy (excl. chemotherapy and radiation therapy)Predictive and prognostic markersEpidemiological methods
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (8)

|May 28, 2026
Human Epidermal Growth Factor Receptor 2 Quantification Using Computational Pathology to Identify Novel Biomarkers for Trastuzumab Deruxtecan-Treated Human Epidermal Growth Factor Receptor 2-Positive Gastric Cancer.

|Sep 04, 2025
Patritumab deruxtecan in HR+HER2- advanced breast cancer: a phase 2 trial.

Barbara Pistilli, Fernanda Mosele, Noemie Corcos

|Dec 16, 2024
The Tumor Immune Microenvironment and Therapeutic Efficacy of Trastuzumab Deruxtecan in Gastric Cancer.

Shigehiro Koganemaru, Shohei Koyama, Fumitaka Suto

|Nov 25, 2024
HER2-related biomarkers predict clinical outcomes with trastuzumab deruxtecan treatment in patients with HER2-expressing metastatic colorectal cancer: biomarker analyses of DESTINY-CRC01.

Salvatore Siena, Kanwal Raghav, Toshiki Masuishi

|Oct 15, 2024
Trastuzumab Deruxtecan with Nivolumab in HER2-Expressing Metastatic Breast or Urothelial Cancer: Analysis of the Phase Ib DS8201-A-U105 Study.

Erika Hamilton, Matthew D Galsky, Sebastian Ochsenreither

|Jul 11, 2024
Patritumab deruxtecan in HER2-negative breast cancer: part B results of the window-of-opportunity SOLTI-1805 TOT-HER3 trial and biological determinants of early response.

Fara Brasó-Maristany, Juan Manuel Ferrero-Cafiero, Claudette Falato

Pageof 2

Frequent Collaborators

4 joint publications

Yusuke Kuwahara

3 joint publications

Hisato Kawakami

3 joint publications

Makito Koga

2 joint publications

Kohei Shitara